{"id":"a-007","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL306791","moleculeType":"Small molecule","molecularWeight":"714.20"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, A-007 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"A-007 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:27:52.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00285207","phase":"PHASE2","title":"Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix","status":"COMPLETED","sponsor":"Tigris Pharmaceuticals","startDate":"2006-01","conditions":"Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia","enrollment":147},{"nctId":"NCT00596258","phase":"PHASE2","title":"A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)","status":"COMPLETED","sponsor":"Tigris Pharmaceuticals","startDate":"2007-11","conditions":"Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia","enrollment":11},{"nctId":"NCT00002153","phase":"PHASE1","title":"Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"A-007","genericName":"A-007","companyName":"DEKK-TEC, Inc.","companyId":"dekk-tec-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A-007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}